INSM Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -225.53% compared to Insmed's net margin of -18.6%. Insmed's return on equity of -41989.34% beat Baxter International's return on equity of -8.24%.

Insmed has a consensus price target of $95.78, signalling upside risk potential of 30.62%. On the other hand Baxter International has an analysts' consensus of $39.87 which suggests that it could grow by 27.16%. Given that Insmed has higher upside potential than Baxter International, analysts believe Insmed is more attractive than Baxter International.

Insmed has a beta of 1.072, which suggesting that the stock is 7.18% more volatile than S&P 500. In comparison Baxter International has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.462%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.94% to investors and pays a quarterly dividend of $0.17 per share. Insmed pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are smaller than Baxter International quarterly revenues of $2.8B. Insmed's net income of -$235.5M is higher than Baxter International's net income of -$512M. Notably, Insmed's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 33.07x versus 1.25x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Biomarin Pharmaceutical has a net margin of -225.53% compared to Insmed's net margin of 16.72%. Insmed's return on equity of -41989.34% beat Biomarin Pharmaceutical's return on equity of 8.09%.

Insmed has a consensus price target of $95.78, signalling upside risk potential of 30.62%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $96.77 which suggests that it could grow by 43.4%. Given that Biomarin Pharmaceutical has higher upside potential than Insmed, analysts believe Biomarin Pharmaceutical is more attractive than Insmed.

Insmed has a beta of 1.072, which suggesting that the stock is 7.18% more volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.302, suggesting its less volatile than the S&P 500 by 69.812%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are smaller than Biomarin Pharmaceutical quarterly revenues of $747.3M. Insmed's net income of -$235.5M is lower than Biomarin Pharmaceutical's net income of $124.9M. Notably, Insmed's price-to-earnings ratio is -- while Biomarin Pharmaceutical's PE ratio is 30.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 33.07x versus 4.69x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Amicus Therapeutics has a net margin of -225.53% compared to Insmed's net margin of 9.85%. Insmed's return on equity of -41989.34% beat Amicus Therapeutics's return on equity of -35.23%.

Insmed has a consensus price target of $95.78, signalling upside risk potential of 30.62%. On the other hand Amicus Therapeutics has an analysts' consensus of $16.73 which suggests that it could grow by 109.09%. Given that Amicus Therapeutics has higher upside potential than Insmed, analysts believe Amicus Therapeutics is more attractive than Insmed.

Insmed has a beta of 1.072, which suggesting that the stock is 7.18% more volatile than S&P 500. In comparison Amicus Therapeutics has a beta of 0.795, suggesting its less volatile than the S&P 500 by 20.519%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Amicus Therapeutics pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are smaller than Amicus Therapeutics quarterly revenues of $149.7M. Insmed's net income of -$235.5M is lower than Amicus Therapeutics's net income of $14.7M. Notably, Insmed's price-to-earnings ratio is -- while Amicus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 33.07x versus 4.61x for Amicus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -225.53% compared to Insmed's net margin of -241.28%. Insmed's return on equity of -41989.34% beat Regenxbio's return on equity of -70.45%.

Insmed has a consensus price target of $95.78, signalling upside risk potential of 30.62%. On the other hand Regenxbio has an analysts' consensus of $32.67 which suggests that it could grow by 389.76%. Given that Regenxbio has higher upside potential than Insmed, analysts believe Regenxbio is more attractive than Insmed.

Insmed has a beta of 1.072, which suggesting that the stock is 7.18% more volatile than S&P 500. In comparison Regenxbio has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.294%.

Insmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insmed pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Insmed quarterly revenues are $104.4M, which are larger than Regenxbio quarterly revenues of $21.2M. Insmed's net income of -$235.5M is lower than Regenxbio's net income of -$51.2M. Notably, Insmed's price-to-earnings ratio is -- while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insmed is 33.07x versus 3.96x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.